Lv24
150 积分 2024-03-21 加入
Resmetirom: The First Disease‐Specific Treatment for MASH
1个月前
已完结
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
1个月前
已完结
Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)
1个月前
已完结
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
1个月前
已完结
Resmetirom: First Approval
1个月前
已完结
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
5个月前
已完结
Beyond resmetirom approval for NAFLD: what has to be done?
7个月前
已完结
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
7个月前
已完结
NAFLD and thyroid function: pathophysiological and therapeutic considerations
1年前
已完结
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
1年前
已完结
皖公网安备34019202002308
